Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

MTLS vs CGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: MTLS 3 – 3 CGEN Matrix Metrics: MTLS 3 – 7 CGEN

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Materialise NV (MTLS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTLS carries a Unified Composite Score of 53.5/100 (HOLD) at $6.29 (N/M Forward P/E, 3.4% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).

  • Composite vs. Pillar Nuance: While MTLS currently prints a higher short-term Unified Composite Score (53.5/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 3.4% operating margin) and revenue trajectory (+102.1% vs. +2.1% YoY).
  • Technical & Structure Timing Caution: MTLS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 31.4); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MTLS vs CGEN
MTLS NASDAQ
Materialise NV
Services-Prepackaged Software
$6.29
+1.29% 1D
Market Cap $369.9M
TTM Revenue $605M
Forward P/E N/M
Beta / 30D Vol 1.10β · 88% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 53.0 Fund 53.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 31
RSI-14: 31.4 · SMA20: $7.28 · SMA50: $7.78
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.74% 1D
Market Cap $198.9M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18

6-Pillar Scorecard Institutional Category Breakdown (MTLS 3 – 3 CGEN)

Columns: Metric · MTLS · CGEN
1. Valuation Multiples CGEN
Forward P/E N/M 12.4x
Trailing P/E 25.0x 5.4x
PEG Ratio 1.26x 1.29x
EV / Revenue 0.6x 2.6x
2. Growth & Scale CGEN
Revenue Growth (YoY) +2.1% +102.1%
Earnings Growth (YoY) -33.3% +0.0%
TTM Revenue (USD) $605M $76M
Market Cap $369.9M $198.9M
3. Profitability & Quality CGEN
Gross Margin 57.4% 86.2%
Operating Margin 3.4% 41.3%
Net Profit Margin 4.6% 47.9%
Return on Equity (ROE) 5.0% 57.2%
4. Balance Sheet & Cash Flow MTLS
Cash Generation (TTM) $55M EBITDA $32M EBITDA
Cash Flow Margin 9.1% EBITDA Mgn 41.9% EBITDA Mgn
Net Cash / Leverage $4.97 Book/Sh · 5.0% ROE $4.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MTLS
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 89.7% (57th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MTLS
OpEx & R&D Intensity 54.0% of Rev ($327M) 44.9% of Rev ($34M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Software - Application Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MTLS (3) vs CGEN (7)
Institutional Metric MTLS CGEN Criterion Row Edge
Market Capitalization
Scale
$369.9M $198.9M Larger Scale MTLS
Trailing P/E Ratio
Valuation
25.0x 5.4x Lower Multiple CGEN
Forward P/E Ratio
Valuation
N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY)
Growth
+2.1% +102.1% Higher Growth CGEN
Operating Margin (TTM)
Profitability
3.4% 41.3% Higher Margin CGEN
Net Profit Margin
Profitability
4.6% 47.9% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
5.0% 57.2% Higher ROE CGEN
52-Week Range Position
Momentum
37% ($5–$9) 33% ($1–$3) Stronger Trend MTLS
Beta / 30D Volatility
Risk Regime
1.10β · 88% Vol 1.44β · 62% Vol Lower Realized Risk CGEN
Unified Institutional Score
Composite Signal
53.5 / 100 (HOLD) 47.1 / 100 (HOLD) Higher Composite MTLS
Trailing 12M Revenue (USD)
Operating Scale
$605M $76M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
57.4% 86.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.26x PEG · 0.6x EV/Rev 1.29x PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$55M EBITDA ($4.97 Book/Sh · 5.0% ROE) $32M EBITDA ($4.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEN +25.18 pp
MTLS: -22.39% · CGEN: +2.79%
3M Horizon MTLS +12.75 pp
MTLS: -4.26% · CGEN: -17.01%
6M Horizon MTLS +38.95 pp
MTLS: +13.13% · CGEN: -25.82%
1Y Horizon CGEN +18.82 pp
MTLS: +4.66% · CGEN: +23.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MTLS vs CGEN. Trailing 12-month operating profitability (MTLS 3.4% vs CGEN 41.3%) and valuation multiples (MTLS N/M vs CGEN 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.

MTLS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$605M
Gross Margin57.4%
Op. Margin3.4%
ROE / Fwd P/E5.0% · N/M
CGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$76M
Gross Margin86.2%
Op. Margin41.3%
ROE / Fwd P/E57.2% · 12.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MTLS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MTLS Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $369.9M market capitalization and 3.4% operating margin.
OpEx & R&D Reinvestment 54.0% of Rev ($327M)
90D Engineering Disclosures 0 Published
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $198.9M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published

Investor FAQ MTLS vs CGEN Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Materialise NV (MTLS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTLS carries a Unified Composite Score of 53.5/100 (HOLD) at $6.29 (N/M Forward P/E, 3.4% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Composite vs. Pillar Nuance: While MTLS currently prints a higher short-term Unified Composite Score (53.5/100 HOLD vs. CGEN 47.1/100 HOLD), CGEN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (41.3% vs. 3.4% operating margin) and revenue trajectory (+102.1% vs. +2.1% YoY). Technical & Structure Timing Caution: MTLS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 31.4); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEN leads the Growth & Scale pillar: MTLS posts +2.1% YoY revenue growth and -33.3% YoY earnings growth on $605M TTM revenue (57.4% gross margin, 3.4% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). On trailing 12-month operating scale, MTLS generates $605M in USD-normalized revenue versus $76M for CGEN. In operating R&D and SG&A reinvestment, MTLS deploys 54.0% of Rev ($327M) (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.

CGEN screens cheaper on headline valuation multiples. MTLS trades at N/M Forward P/E, 25.0x Trailing P/E, 1.26x PEG, and 0.6x EV/Revenue (9.1% EBITDA margin), whereas CGEN trades at 12.4x Forward P/E, 5.4x Trailing P/E, 1.29x PEG, and 2.6x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTLS (5.0% ROE) versus CGEN (57.2% ROE) capital efficiency.

In options market volatility and institutional positioning, MTLS carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.10β · 88% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.